I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003-2013, by ….) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate … of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months)- about 44% of the total increase in longevity -and … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma … post-1997 chemotherapy innovation did not exceed $45,551. We also investigate the impact of chemotherapy innovation on the …, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) — about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

important innovations since 1997. We investigate the impact of recent chemotherapy innovation on the longevity of myeloma … post-1997 chemotherapy innovation did not exceed $45,551. We also investigate the impact of chemotherapy innovation on the …, controlling for other factors. The estimates imply that chemotherapy innovation reduced the age-adjusted myeloma cancer mortality …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003–2013, by ….) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate … of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months)-—about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …